癌症單株抗體市場規模、佔有率和成長分析（按類型、應用、最終用戶和地區）：產業預測（2024-2031）

2022年全球癌症單株抗體市場規模估值為739億美元，從2023年的875億美元擴大到2031年的3379.2億美元，在預測期內（2024-2031）預計複合年成長率為18.40% 。

單株抗體 (mAb) 療法越來越被認為是癌症治療的重要組成部分，是化療、放射線治療和手術等傳統治療方法的補充。在過去的二十年中，單株抗體已被確立為治療固體癌和骨髓惡性腫瘤的高效治療方法，刺激了癌症發病率的上升和新藥認證的強勁管道。目前和即將核准的單株抗體療法與傳統化療相比具有副作用相對較少的治療優勢，並有可能使全世界數百萬人受益。醫療保健提供者對負擔得起的生物相似藥單株抗體的接受程度不斷提高，預計將在預測期內進一步促進市場成長。然而，COVID-19 疫情對癌症篩檢率產生了負面影響，與先前相比，2020 年 4 月乳癌篩檢率大幅下降了 87%。這種下降導致了治療的嚴重延誤，引發了人們對及時獲得所需抗癌藥物、疾病復發和治療延遲的擔憂。由於癌症仍然是一種以不受控制的細胞增殖為特徵的主要慢性疾病，癌症發生率的上升可能會繼續推動對單株抗體療法的需求並支持市場擴張。總體而言，在創新癌症治療的需求和疫情後醫療保健取得的發展的推動下，癌症市場的單株抗體領域有望成長。

目錄

介紹

• 分析目的
• 定義
• 市場範圍

分析方法

• 資訊採購
• 二手資料來源和主要資料來源
• 市場規模預測
• 市場假設與限制

執行摘要

• 市場概況及展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場動態
  • 促進因素
  • 機會
  • 抑制因素
  • 任務
• 波特的分析

主要市場考察

• 技術分析
• 價值鏈分析
• 市場生態系統
• 案例研究分析
• 監管環境
• 創新矩陣
• 主要投資分析
• 關鍵成功因素
• 競爭程度

癌症單株抗體市場：依類型

• 市場概況
• 人性化
• 人類
• 嵌合體
• 老鼠

癌症單株抗體市場：依應用分類

• 市場概況
• 血癌
• 乳癌
• 肺癌
• 惡性黑色素瘤
• 大腸直腸癌
• 肝癌
• 其他

癌症單株抗體市場：依最終用戶分類

• 市場概況
• 醫院
• 研究所
• 其他

癌症單株抗體市場：按地區

• 市場概況
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲 (MEA)
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲

競爭格局

• 前5名企業對比
• 主要企業市場定位（2023年）
• 主要市場參與者所採取的策略
• 近期市集活動
• 主要企業市場佔有率（2023年）

主要企業簡介

• 艾伯維公司（美國）
• 安進公司（美國）
• 默克公司（美國）
• 百時美施貴寶公司（美國）
• 吉利德科學公司（美國）
• 武田製藥公司（日本）
• 阿斯特捷利康公司（英國）
• 禮來公司（美國）
• 再生元製藥公司（美國）
• 百濟神州有限公司 (中國)
• 百健公司（美國）
• Recordati Industria Chimica e Farmaceutica SpA（義大利）
• 輝瑞（美國）
• Spectrum Pharmaceuticals, Inc.（美國）
• Iovance Biotherapeutics, Inc.（美國）
• Exelixis, Inc.（美國）
• OncoOne（美國）
• CureVac AG（德國）
• Cellerant Therapeutics, Inc.（美國）
• Celltrion, Inc.（韓國）
• Faron 製藥股份有限公司（芬蘭）

Global Cancer Monoclonal Antibodies Market size was valued at USD 73.9 billion in 2022 and is poised to grow from USD 87.5 billion in 2023 to USD 337.92 billion by 2031, growing at a CAGR of 18.40% during the forecast period (2024-2031).

Monoclonal antibody (mAb) therapies are increasingly recognized as crucial components in the cancer treatment landscape, complementing traditional modalities such as chemotherapy, radiation, and surgery. Over the past two decades, mAbs have established themselves as highly effective treatments for both solid tumors and hematologic malignancies, spurred by rising cancer incidence rates and a robust pipeline of new drug approvals. Current and forthcoming mAb therapies hold the potential to benefit millions globally, offering a therapeutic advantage due to their relatively lower side effects compared to conventional chemotherapy. The growing acceptance of affordable biosimilar monoclonal antibodies by healthcare providers is expected to further enhance market growth in the forecast period. However, the COVID-19 pandemic has negatively impacted cancer screening rates, with a dramatic 87% drop observed in breast cancer screenings in April 2020 compared to previous years. This decline resulted in significant treatment delays, raising concerns about timely access to necessary cancer medications, disease recurrence, and the postponement of therapies. As cancer remains a major chronic disease characterized by unchecked cell proliferation, the escalating incidence of cancer cases will likely continue to drive demand for mAb therapies and bolster market expansion in the coming years. Overall, the mAb segment of the oncology market stands poised for growth, fueled by both the need for innovative cancer treatments and the evolution of healthcare access in a post-pandemic landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cancer Monoclonal Antibodies market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cancer Monoclonal Antibodies Market Segmental Analysis

Global Cancer Monoclonal Antibodies Market is segmented by Type, Application, End-user, end user and region. Based on Type, the market is segmented into Humanized, Human, Chimeric, and Murine. Based on Application, the market is segmented into Blood Cancer, Breast Cancer, Lung Cancer, Melanoma, Colorectal Cancer, Liver Cancer, and Others. Based on End-user, the market is segmented into Hospitals, Research Institutes, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Cancer Monoclonal Antibodies Market

The Global Cancer Monoclonal Antibodies market is significantly driven by the alarming rise in cancer prevalence worldwide, which underscores the urgent need for innovative and effective treatment options. Monoclonal antibodies are favored over traditional therapies due to their ability to selectively target malignant cells, thereby improving treatment efficacy and minimizing adverse effects. As patient demand for advanced therapeutic solutions escalates, the market is further bolstered by increased investments in research and development aimed at discovering novel monoclonal antibody-based therapies. Furthermore, heightened awareness surrounding cancer leads to earlier detection and treatment initiation, propelling growth and development within this vital sector of oncology.

Restraints in the Global Cancer Monoclonal Antibodies Market

A significant market restraint for the global cancer monoclonal antibodies market is the prohibitively high cost associated with monoclonal antibody therapies. The advanced manufacturing processes and extensive research and development required for these therapies contribute to their steep pricing. This financial burden limits patient access, particularly among low-income communities and in countries with strained healthcare budgets. As a result, the expensive nature of these treatments may render them unaffordable for many, leading to increased out-of-pocket expenses and further hindering market growth and accessibility. This economic barrier could ultimately restrict the adoption of these potentially life-saving therapies across diverse populations.

Market Trends of the Global Cancer Monoclonal Antibodies Market

The Global Cancer Monoclonal Antibodies market is witnessing a significant trend towards the integration of combination therapies, reflecting an evolving landscape in oncology treatment. By leveraging monoclonal antibodies in conjunction with immunotherapies, targeted therapies, and chemotherapy, healthcare providers aim to combat cancer on multiple fronts, enhancing treatment efficacy while minimizing resistance. The synergistic effects observed, particularly with immune checkpoint inhibitors paired with monoclonal antibodies, underscore the potential for improved patient outcomes through deeper immune responses against tumors. This trend not only highlights the complexity of cancer but also emphasizes the shift towards personalized medicine, offering tailored and potent treatment options for diverse patient profiles.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Technology Analysis
• Value Chain Analysis
• Ecosystem of the Market
• Case study Analysis
• Regulatory Landscape
• Innovation Matrix
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Cancer Monoclonal Antibodies Market by Type

• Market Overview
• Humanized
• Human
• Chimeric
• Murine

Cancer Monoclonal Antibodies Market by Application

• Market Overview
• Blood Cancer
• Breast Cancer
• Lung Cancer
• Melanoma
• Colorectal Cancer
• Liver Cancer
• Others

Cancer Monoclonal Antibodies Market by End-user

• Market Overview
• Hospitals
• Research Institutes
• Others

Cancer Monoclonal Antibodies Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• AbbVie Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BeiGene, Ltd (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Recordati Industria Chimica e Farmaceutica S.p.A (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Spectrum Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Iovance Biotherapeutics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exelixis, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• OncoOne (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CureVac AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cellerant Therapeutics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celltrion, Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Faron Pharmaceuticals Ltd. (Finland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments